Inflation is slowing, and that could be great news for growth stocks as it potentially opens up the door to lower interest rates. And there are some particularly good growth opportunities within healthcare that investors shouldn't overlook right now. A couple of stocks that Wall Street analysts think could double in value are Viridian Therapeutics (NASDAQ: VRDN) and Ginkgo Bioworks (NYSE: DNA). Here's a closer look at these two businesses.

Viridian Therapeutics' market capitalization is at just about $1 billion. Only its  collaboration revenue contributes to its top line today. But if the company, which focuses on rare diseases, can get an approved product that it can rely on for long-term growth, this biotech could have plenty of upside. 

According to Wall Street analysts, the stock could already jump as high as $45 within the next year or so, which is the consensus analyst price target. The healthcare stock closed at just over $22 last week, meaning that if it were to reach that price target, it would more than double in value. 

Continue reading

Source Fool.com